Lawyers Offer Free Actos Bladder Cancer Claims Consultation

The bladder cancer attorneys of Onder, Shelton, O’Leary & Peterson, LLC are offering Actos users diagnosed with bladder cancer a no-cost, no-obligation Actos bladder cancer claim review.

Saturday, January 28, 2012 - The Onder Law Firm, a national law firm handling serious injury, death, and dangerous drug cases, is currently responding to the increased need for legal representation by users of the popular diabetes drug Actos whom have been diagnosed with bladder cancer. Actos bladder cancer claims have risen sharply since the FDA updated its Actos bladder cancer warning. Actos is a medication used to control blood sugar in adults with Type 2 diabetes that was approved by the FDA in 1999. It was recently the top-selling medication of its type in the United States, with more than 2 million users per year. Actos is manufactured by Takeda Pharmaceuticals, Inc., the largest pharmaceutical firm in Japan.

In September of 2010, the FDA issued its first Actos bladder cancer warning, stating that the risk of developing bladder cancer could increase after using Actos for two or more years. Less than ten months later, in June of 2011, the FDA updated that safety notice, reducing the duration of Actos use necessary to increase bladder cancer risks to just one year.

The Onder Law Firm, a prominent national law firm with a long history of representing clients harmed by dangerous drugs and defective medical devices, is offering a free, no-obligation Actos bladder cancer claim review to families of persons who have been diagnosed with bladder cancer after using Actos. The Onder Law Firm‘s Actos bladder cancer lawyers are handling all Actos bladder cancer lawsuits on a contingency basis. The law firm has created an Actos bladder cancer website with information about both Actos and bladder cancer litigation.

The Onder Law Firm welcomes Actos bladder cancer inquiries from law firms wishing to refer their cases or working as co-counsel.

Other Actos Lawsuit Attorney News Releases:

Ad